Anti-Cholinergic Effects of the Phenolic Extract from the Astragalus crenatus Plant: A Computational and Network Pharmacology Study

A tardive dyskinesia drug target VMAT-2 participates in neuronal process elongation

Tardive dyskinesia involves involuntary movements of body parts and is often observed in individuals taking antipsychotics for extended periods. Initial treatment strategies include reducing medication dosage, switching medications, or using drugs to suppress symptoms. One of the therapeutic targets for tardive dyskinesia is vesicular monoamine transporter-2 (VMAT-2, also known as solute carrier family 18 member A2 [SLC18A2]), which functions as an energy-dependent transporter of monoamines. The therapeutic drugs are used during adulthood, when neurons are maturing. For the first time, we report that treatment with a chemical VMAT-2 inhibitor reduces neuronal process elongation, a phenomenon commonly observed during development. Treatment with the inhibitors reserpine or tetrabenazine decreased process elongation in primary cortical neurons, and similar results were obtained in N1E-115 neuronal model cells undergoing process elongation. Knockdown of VMAT-2 using clustered regularly interspaced short palindromic repeat (CRISPR)/Cas13-fitted guide RNA also reduced process elongation. However, treatment with reserpine or tetrabenazine did not affect the morphology of mature processes. Notably, treatment with hesperetin, a citrus flavonoid with neuroprotective effects, was able to restore the reduced process elongation induced by these inhibitors or VMAT-2 knockdown. The underlying molecular mechanism appeared to involve neuronal differentiation-related Akt kinase signaling. These results suggest that VMAT-2, as a drug target for tardive dyskinesia, plays a key role in process elongation and that some inhibitory effects of VMAT-2-targeted drugs on its elongation may be mitigated by co-administering a neuroprotective molecule.

LC-HRMS Profiling of Phytochemicals with Assessment of Antioxidant, Anticholinesterase, and Antimicrobial Potentials of Astragalus Brachystachys DC

Astragalus species are ubiquitous in the pharmacopeia of numerous countries, signifying their widespread medicinal applications. Türkiye is esteemed as one of the principal epicenters of diversity for this genus with 483 taxa, and many of these plants have been traditionally utilized for diseases including coughing, diabetes, cardiovascular disorders, and aches. Although there is a considerable body of chemical and biological research available on several Astragalus species, studies focusing on Astragalus brachystachys DC are exceedingly rare. In this context, This study provides the first comprehensive report on this medicinal plant the chemical constituents and biological activities of an important medicinal plant, Astragalus brachystachys DC. The aerial part samples were collected from Adana, Türkiye, and an ethanol extract was prepared with these parts. The secondary metabolites of the extract were determined by an LC-HRMS analysis. The LC-HRMS analysis showed the presence of 39 different constituents, hyperoside (303.419±10.50 μg/g extract), p-coumaric acid (256.975±8.51 μg/g extract), and rutin (72.684±2.23 μg/g extract) were determined as major compounds in the aerial parts ethanol extract. Attributed to its high total phenolic (58.53±1.30 μg PEs/mg extract) and total flavonoid content (29.98±0.83 μg QEs/mg extract), the extract demonstrated strong antioxidant activity according to three different assays namely DPPH free (IC50: 33.08±0.61 μg/mL), and ABTS cation radical scavenging (IC50: 15.39±0.72 μg/mL) and CUPRAC activity (A0.5: 36.25±0.28 μg/mL) methods. In vitro assays showed that cholinesterase inhibitory activity results were found to be exceptional with 85.95±0.52 % inhibition on acetylcholinesterase and 66.32±1.33 % inhibition on butyrylcholinesterase at 200 μg/mL. Regarding antimicrobial properties, Astragalus brachystachys DC extract was found to be effective against Enterococcus faecalis with a MIC value of 39.06 μg/mL.

Silymarin as a Therapeutic Agent for Hepatocellular Carcinoma: A Multi-Approach Computational Study

BACKGROUND

Hepatocellular carcinoma (HCC) is a prevalent and lethal form of liver cancer with limited treatment options. Silymarin, a flavonoid complex derived from milk thistle, has shown promise in liver disease treatment due to its antioxidant, anti-inflammatory, and anticancer properties. This study aims to explore the therapeutic potential of silymarin in HCC through a comprehensive in silico approach.

METHODS

This study employed a network pharmacology approach to identify key molecular targets of silymarin in HCC. The Genecards and Metascape databases were used for target identification and functional annotation. Molecular docking analysis was conducted on the primary silymarin components against VEGFA and SRC proteins, which are critical in HCC progression. MD simulations followed to assess the stability and interactions of the docked complexes.

RESULTS

Network pharmacology analysis identified several key molecular targets and pathways implicated in HCC. The molecular docking results revealed strong binding affinities of silymarin components to VEGFA and SRC, with Silybin A and Isosilybin B showing the highest affinities. MD simulations confirmed the stability of these interactions, indicating potential inhibitory effects on HCC progression.

CONCLUSIONS

This study provides a comprehensive in silico evaluation of silymarin's therapeutic potential in HCC. The findings suggest that silymarin, particularly its components Silybin A and Isosilybin B, may effectively target VEGFA and SRC proteins, offering a promising avenue for HCC treatment. Further experimental validation is warranted to confirm these findings and facilitate the development of silymarin-based therapeutics for HCC.

Bioactive Phenolics of Hyoscyamus muticus L. Subsp. Falezlez: A Molecular and Biochemical Approach to Antioxidant and Urease Inhibitory Activities

This study examines the chemical composition, antioxidant properties, and urease inhibitory effects of Hyoscyamus muticus L. subsp. falezlez (Coss.) Maire. Using LC-ESI-MS/MS, 19 distinct phenolic compounds were identified, with chlorogenic acid being the most abundant. The ethanol extract demonstrated notable antioxidant activity, highlighting its potential for therapeutic use. Urease inhibition assays revealed a remarkable 91.35% inhibition by the H. muticus extract, with an IC50 value of 5.6 ± 1.20 μg/mL, indicating its promising role in addressing conditions linked to urease activity. Molecular docking studies further investigated the interaction between H. muticus phenolic compounds and urease, identifying hyperoside as a leading candidate, with a binding energy of -7.9 kcal/mol. Other compounds, such as rutin, luteolin, apigenin, kaempferol, hesperetin, chlorogenic acid, and rosmarinic acid, also demonstrated significant binding affinities, suggesting their potential to disrupt urease function. These findings highlight the therapeutic potential of H. muticus as a source of natural bioactive compounds, offering promising avenues for the development of novel treatments for urease-related disorders and oxidative stress.

Preliminary Data on Silybum marianum Metabolites: Comprehensive Characterization, Antioxidant, Antidiabetic, Antimicrobial Activities, LC-MS/MS Profiling, and Predicted ADMET Analysis

BACKGROUND/OBJECTIVES

Silybum marianum extract, obtained via microwave-enhanced extraction, was evaluated for its antioxidant, antidiabetic, and antimicrobial activities to explore its therapeutic potential.

METHODS

The extraction was performed using microwave-enhanced techniques, and LC-MS/MS was employed to profile the metabolites in the extract. Total phenolic and flavonoid contents were quantified using spectrophotometric methods. Antioxidant activity was assessed using DPPH, ABTS, CUPRAC, Phenanthroline, and FRAP assays. Enzyme inhibition assays were conducted to evaluate antidiabetic activity against α-glucosidase and α-amylase. Antimicrobial activity was determined using the disc diffusion method, and in silico ADMET and drug-likeness analyses were performed for key metabolites.

RESULTS

The extract contained 251.2 ± 1.2 mg GAE/g of total phenolics and 125.1 ± 1.6 mg QE/g of total flavonoids, with 33 metabolites identified, including phenolic acids, tannins, flavonoids, and flavolignans. Strong antioxidant activity was observed, with IC50 values of 19.2 ± 2.3 μg/mL (DPPH), 7.2 ± 1.7 μg/mL (ABTS), 22.2 ± 1.2 μg/mL (CUPRAC), 35.2 ± 1.8 μg/mL (Phenanthroline), and 24.1 ± 1.2 μg/mL (FRAP). Antidiabetic effects were significant, with IC50 values of 18.1 ± 1.7 μg/mL (α-glucosidase) and 26.5 ± 1.3 μg/mL (α-amylase). Antimicrobial activity demonstrated inhibition zones of 8.9 ± 1.1 mm (Bacillus subtilis), 12.6 ± 1.6 mm (Escherichia coli), 8.2 ± 1.2 mm (Fusarium oxysporum), and 9.2 ± 1.1 mm (Aspergillus niger). In silico analyses showed high absorption, favorable metabolism and excretion, and minimal toxicity, with no hERG channel inhibition or hepatotoxicity.

CONCLUSIONS

The comprehensive results highlight the significant antioxidant, antidiabetic, and antimicrobial activities of S. marianum extract, suggesting its potential for therapeutic and preventive applications.

From Green Chemistry to Healthy Environments: Silver Nanoparticles as a Dual Antioxidant and Antibacterial Agents for Advancing Biomedicine and Sustainable Wastewater Treatment

The green synthesis of silver nanoparticles (AgNPs) using plant extracts is an eco-friendly method with potential for biomedical and environmental applications. This study aims to synthesize silver nanoparticles (SO-AgNPs) using Salvia officinalis L. extract and evaluate their antioxidant and antibacterial properties, positioning them as candidates for applications in sustainable biomedicine and wastewater treatment. S. officinalis L. extract was used to synthesize AgNPs under optimized conditions, with a 10% extract/AgNO₃ ratio and a reaction time of 180 min. The SO-AgNPs were characterized using ATR-FTIR, XRD, SEM, DLS, and Zeta potential analysis. The antioxidant activity of the extract and SO-AgNPs was evaluated using ABTS+• and DPPH• radical scavenging assays. Antibacterial activity was tested against 11 bacterial strains and bacteria isolated from industrial effluent, with minimal inhibitory concentrations (MIC) determined for both the extract and SO-AgNPs. The SO-AgNPs demonstrated potent antioxidant activity, with IC₅₀ values of 0.233 mg/mL and 0.305 mg/mL in the ABTS+• assay, and 0.173 mg/mL and 0.185 mg/mL in the DPPH• assay for the extract and SO-AgNPs, respectively. Antibacterial testing showed MIC values of 0.25 mg/mL for SO-AgNPs and between 3.12 and 6.25 mg/mL for S. officinalis L. extract against E. coli, P. aeruginosa, A. baumannii, MRSA, B. cereus, and S. epidermidis. For bacteria isolated from industrial effluent, the MIC values were 0.125 mg/mL for SO-AgNPs and 0.5 mg/mL for the extract. This study highlights the dual antioxidant and antibacterial capabilities of S. officinalis L. extract and SO-AgNPs, demonstrating their potential for use in both biomedical and environmental applications, including wastewater treatment.

Systematic investigation on the pharmaceutical components and mechanism of the treatment against zebrafish enteritis by Sporisorium reilianum f. sp. reilianum based on histomorphology and pathology

ETHNOPHARMACOLOGICAL RELEVANCE

Sporisorium reilianum f. sp. reilianum (SSR) is a fungus isolated from a medicinal plant. Recorded in the "Compilation of National Chinese Herbal Medicine" and "Compendium of Materia Medica," it was used for preventing and treating intestinal diseases, enhancing immune function, etc. In this study, we investigated the chemical composition and bioactivity of SSR. Network pharmacology is utilized for predictive analysis and targeting pathway studies of anti-inflammatory bowel disease (IBD) mechanisms. Pharmacological activity against enteritis is evaluated using zebrafish (Danio rerio) as model animals.

AIM OF THE STUDY

To reveal the treatment of IBD by SSR used as traditional medicine and food, based on molecular biology identification of SSR firstly, and the pharmaceutical components & its toxicities, biological activity & mechanism of SSR were explored.

MATERIALS AND METHODS

Using chromatography and zebrafish IBD model induced by dextran sulfate sodium (DSS), nine compounds were first identified by nuclear magnetic resonance (NMR). The toxicity of ethanol crude extract and monomers from SSR were evaluated by evaluating the phenotypic characteristics of zebrafish embryos and larvae, histomorphology and pathology of the zebrafish model guided by network pharmacology were conducted.

RESULTS

The zebrafish embryo development did not show toxicity. The molecular docking and enrichment pathway results predicted that metabolites 3 & 4 (N-trans- feruloyl-3-methoxytyramine & N-cis-feruloyl-3-methoxytyramine) and 7 & 8 (4-N- trans-p-coumaroyltyramine & 4-N-cis--p-coumaroyltyramine) have anti-enteritis activities. This paper lays an experimental foundation for developing new drugs and functional foods.